Navigation Links
Afraxis, Inc. and Servier Announce a Collaboration on ESP Platform for Drug Discovery in Central Nervous System Disorders
Date:4/30/2013

SAN DIEGO and PARIS, April 30, 2013 /PRNewswire/ -- Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology for the discovery of drugs to treat central nervous system (CNS) disorders.  Afraxis' ESP Technology rapidly assesses complex neural networks to evaluate preclinical efficacy and safety in CNS disorders. The technology quantifies and characterizes the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing in the brain. Financial terms have not been disclosed.

"Servier is committed to bringing new medicines for the treatment of a variety of CNS diseases and disorders," said Dr. Emmanuel Canet , President of Servier Research & Development. "We recognize that Afraxis is a global leader in dendritic spine analysis which provides a sophisticated and quantifiable read-out on neuroprotection."

Dr. Christian de Bodinat, Director of CNS Research & Development added, "The ESP Technology will allow Servier to fully investigate the broad potential of our drug candidates with the aim of bringing novel medicines into the clinic more rapidly and with greater certainty of action. Servier is very active in the field of neurology with two potential first-in-class compounds in Phase II studies in Alzheimer Disease and five other compounds aimed at treating neurodegenerative diseases in late preclinical stages."

The Afraxis ESP Technology is highly adaptable to many CNS disease models and can be used to characterize disease profiles, assess preclinical drug efficacy, identify optimal dosing routines, or identify undesirable CNS side effects. 

"Servier has a strong commitment to CNS therapeutics, and their interest in the ESP Technology further illustrates the potential of this platform in a drug discovery setting," said Carmine Stengone , president and CEO of Afraxis.  "We are excited to kick-off this collaboration with Servier and look forward to a fruitful relationship."

About Servier
Servier is the leading independent French pharmaceutical company with a 2012 turnover of €3.9 billion. The Servier Group is established in 140 countries with its main therapeutic products used to treat diabetes, cardiovascular diseases, CNS disorders, oncology and rheumatological diseases. More than 25% of Servier's revenue is invested in Research & Development. Servier has 20,000 employees worldwide, including nearly 3,000 in R&D. For further information, please visit www.servier.com.

About Afraxis, Inc.
Afraxis, Inc. is a San Diego-based drug discovery platform company recently spun-out of Afraxis Holdings. The company is part of a growing wave of innovative neuroscience that applies cutting-edge technical and computational approaches to fundamental issues in brain science that promise to generate new insights into CNS diseases. Afraxis develops and uses high-content central nervous system (CNS) pharmaceutical screening technologies to evaluate preclinical efficacy for potential treatments for neurological and psychiatric disorders.  Afraxis developed the Enhanced Spine Platform (ESP) Technology platform, which quantifies the morphology and maturity of synaptic dendritic spines which are fundamental to information processing by neural synapses in the brain. Abnormal dendritic spine quantity and morphology have been associated with numerous CNS disorders, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism. Afraxis has a strategic alliance with PsychoGenics to offer its ESP Technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery science.


'/>"/>
SOURCE Afraxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NextBio Announces Translational Medicine Partnership with Sanofi
2. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
3. IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries
4. Kewaunee Scientific Announces CEO Retirement and Appointment of Successor
5. Blue Belt Technologies Announces Formation of Hip Scientific Advisory Board for Development of Next NavioPFS Application for Femoroacetabular Impingement
6. FDAnews Announces Medical Device Risk Management Conference, July 11-12, 2013, Boston, MA
7. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
8. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
9. ConvaTec Announces 2012 Year-End Earnings Call
10. Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
11. Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):